Nathalie Ganne‐Carrié

机构：Inserm, Université Paris Cité, Sorbonne Université, Université Sorbonne Paris Nord, Sorbonne Paris Cité, Centre de Recherche des Cordeliers, Assistance Publique – Hôpitaux de Paris, Hôpital Avicenne · ORCID：0000-0002-7351-5027

发表论文 397 篇 · 总被引 13580 次 · h-index 60

代表论文

• [18F]fluorodeoxyglucose and [18F]fluorocholine PET-CT for staging optimisation and treatment modification in hepatocellular carcinoma (PET-HCC01): a prospective multicentre study (2025 · ˜The œLancet. Gastroenterology & hepatology · 被引 13)
• Real‐World Outcomes of Atezolizumab–Bevacizumab in Hepatocellular Carcinoma: The Prospective French CHIEF Cohort (2025 · Liver International · 被引 8)
• Survival in patients receiving reduced dose intensity of bevacizumab for unresectable hepatocellular carcinoma (2025 · npj Precision Oncology · 被引 7)
• Value of non-invasive test dynamics in guiding HCC surveillance decisions after HCV cure in patients with cirrhosis (2025 · Journal of Hepatology · 被引 7)
• HBsAg decline and clearance with peg-IFN therapy added to nucleos(t)ide analogues: an individual participant data meta-analysis of prospective trials (PROSPER) (2025 · Gut · 被引 6)
• Real-life data on hepatocellular carcinoma in the French prospective CHIEF cohort in the era of immunotherapy (2025 · European Journal of Gastroenterology & Hepatology · 被引 4)